FOCUS Study Shows MammaPrint® Accurately Identifies Extremely Indolent Cancers

IRVINE, Calif., & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, presented data from the FOCUS trial that show the clinical utility of MammaPrint® in older breast cancer patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). The poster, The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients, outlines data from the FOCUS trial, a population-based cohort of over 2,000 people

Click to view original post